Sensor could help doctors select effective cancer therapy

Hydrogen peroxide-sensing molecule reveals whether chemotherapy drugs are having their intended effects.

MIT chemical engineers have developed a new sensor that lets them see inside cancer cells and determine whether the cells are responding to a particular type of chemotherapy drug.

The sensors, which detect hydrogen peroxide inside human cells, could help researchers identify new cancer drugs that boost levels of hydrogen peroxide, which induces programmed cell death. The sensors could also be adapted to screen individual patients’ tumors to predict whether such drugs would be effective against them.

“The same therapy isn’t going to work against all tumors,” says Hadley Sikes, an associate professor of chemical engineering at MIT. “Currently there’s a real dearth of quantitative, chemically specific tools to be able to measure the changes that occur in tumor cells versus normal cells in response to drug treatment.”

Sikes is the senior author of the study, which appears in the Aug. 7 issue of Nature Communications. The paper’s first author is graduate student Troy Langford; other authors are former graduate students Beijing Huang and Joseph Lim and graduate student Sun Jin Moon.

Tracking hydrogen peroxide

Cancer cells often have mutations that cause their metabolism to go awry and produce abnormally high fluxes of hydrogen peroxide. When too much of the molecule is produced, it can damage cells, so cancer cells become highly dependent on antioxidant systems that remove hydrogen peroxide from cells.

Drugs that target this vulnerability, which are known as “redox drugs,” can work by either disabling the antioxidant systems or further boosting production of hydrogen peroxide. Many such drugs have entered clinical trials, with mixed results.

“One of the problems is that the clinical trials usually find that they work for some patients and they don’t work for other patients,” Sikes says. “We really need tools to be able to do more well-designed trials where we figure out which patients are going to respond to this approach and which aren’t, so more of these drugs can be approved.”

To help move toward that goal, Sikes set out to design a sensor that could sensitively detect hydrogen peroxide inside human cells, allowing scientists to measure a cell’s response to such drugs.

Existing hydrogen peroxide sensors are based on proteins called transcription factors, taken from microbes and engineered to fluoresce when they react with hydrogen peroxide. Sikes and her colleagues tried to use these in human cells but found that they were not sensitive in the range of hydrogen peroxide they were trying to detect, which led them to seek human proteins that could perform the task.

Through studies of the network of human proteins that become oxidized with increasing hydrogen peroxide, the researchers identified an enzyme called peroxiredoxin that dominates most human cells’ reactions with the molecule. One of this enzyme’s many functions is sensing changes in hydrogen peroxide levels.

Langford then modified the protein by adding two fluorescent molecules to it — a green fluorescent protein at one end and a red fluorescent protein at the other end. When the sensor reacts with hydrogen peroxide, its shape changes, bringing the two fluorescent proteins closer together. The researchers can detect whether this shift has occurred by shining green light onto the cells: If no hydrogen peroxide has been detected, the glow remains green; if hydrogen peroxide is present, the sensor glows red instead.

Predicting success

The researchers tested their new sensor in two types of human cancer cells: one set that they knew was susceptible to a redox drug called piperlongumine, and another that they knew was not susceptible. The sensor revealed that hydrogen peroxide levels were unchanged in the resistant cells but went up in the susceptible cells, as the researchers expected.

Sikes envisions two major uses for this sensor. One is to screen libraries of existing drugs, or compounds that could potentially be used as drugs, to determine if they have the desired effect of increasing hydrogen peroxide concentration in cancer cells. Another potential use is to screen patients before they receive such drugs, to see if the drugs will be successful against each patient’s tumor. Sikes is now pursuing both of these approaches.

“You have to know which cancer drugs work in this way, and then which tumors are going to respond,” she says. “Those are two separate but related problems that both need to be solved for this approach to have practical impact in the clinic.”

The research was funded by the Haas Family Fellowship in Chemical Engineering, the National Science Foundation, a Samsung Fellowship, and a Burroughs Wellcome Fund Career Award at the Scientific Interface.

Featured Research

Model helps robots navigate more like humans do

In simulations, robots move through new environments by exploring, observing, and drawing from learned experiences. When moving throu...

AC Investment Group Key Financial & Operational Data (Quarterly)*

(million $)
EBITDA margin34.5%37.3%42.5%8.0pp5.2pp
Net income4,502,164,019.2%132.0%
AC Invest Jersey3,53,673,34.2%1.6%
AC Invest London5,05,25,1(0.6%)(0.2%)
*Based on figures prepared by IFRS;
**EBITDA is a non-GAAP financial measure.

We invest in high tech companies.*

DialPad Flatiron Health Stripe Acalvio Editas Medicine Foundation Medicine

(Investments $)20172018
Life Science
Data and AI

Our companies push the edge of what’s possible.

We help build successful companies.

Board of Directors Investor Relations and Financials

Our story.

Launched as A/C Investment in 2017, A/C is the venture capital arm of AC ADV Inc. A/C has $112 million under management with 42 investments

A/C Invest built a team of world-class economists, physicians, scientists, marketers, and investors who work together to provide these startups exceptional support on the road to business shift.

Adem Çetinkaya

Adem Çetinkaya Yatırım A.Ş. adem çetinkaya faiz oranlı swap ve açık piyasa işlemleri adem çetinkaya venture capital işlemleri yapılmaktadır. Adem Çetinkaya finansal swap riskinin hesaplanması ve azaltılmasında tezgah üstü piyasa işlmleri kullanılmaktadır.Cambridge, London ve Jersey adasında çoğunlukla devlet kurumları ve uluslararası şirketler adına swap ve offshore yatırım işlemleri yapmaktadır.Faiz oranlı swap işlemlerinin yapılandırılması, değiştirilmesi ve sonlandırılması ile faiz oranlı takasların opsiyon temelli özelliklerinde caps ve floor gibi ilgili finansal risklerin tespit edilerek yönetilmesi gerekm Offshore piyasası uluslararası yatırımlar için fırsatlaAr yaratsa da, offshore işlemlerde mali suçların önlenmesi ve uluslararası regülasyonların gözetilmesi gerekmektedir. ektedir.
Feel free to drop us a line to contact us
301 Massachusetts Avenue Cambridge, MA 02139